Health Professional Radio - Podcast

Dr. Kirk Shepard, CMO, SVP, & Head of Global Medical Affairs, Oncology Business Group at Eisai Inc, discusses the final study results from the KEYNOTE-146/Study 111 presented at the 2019 European Society for Medical Oncology (ESMO) Congress, evaluating KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) combination for the treatment of advanced endometrial cancer. Merck and Eisai known as MSD outside the United States and Canada, are in collaboration for the worldwide co-development and co-commercialization of LENVIMA.